Pipeline of Nectin-4-Targeted Immunotherapies

Nectin-4: a clinically and commercially validated target with limited competition – a pipeline review STUTTGART, Germany I August 26, 2025 I La Merie Publishing announced the release of its newest product offering reviewing the pipeline of active anti-nectin-4 immunotherapeutics in R&D: Pipeline of Nectin-4-Targeted Immunotherapies. This competitive intelligence report about...

Pipeline of CCR8-Targeted Immunotherapies

CCR8: an attractive immuno-oncology target for antibody therapy – a pipeline review STUTTGART, Germany I August 20, 2025 I La Merie Publishing announced the release of its newest product offering reviewing the pipeline of active anti-CCR8 immunotherapeutics in R&D: Pipeline of CCR8-Targeted Immunotherapies. This competitive intelligence report about CCR8-Targeted Immunotherapies...

Pipeline of EpCAM-Targeted Immunotherapies

EpCAM: conditional activation technologies can make EpCAM a viable target – a pipeline review STUTTGART, Germany I August 19, 2025 I La Merie Publishing announced the release of its newest product offering reviewing the pipeline of active anti-EpCAM immunotherapeutics in R&D: Pipeline of EpCAM-Targeted Immunotherapies. This competitive intelligence report about...

Pipeline of B7-H4-Targeted Immunotherapies

B7-H4: a promising target for effector-enhanced drug modalities – a pipeline review STUTTGART, Germany I August 18, 2025 I La Merie Publishing announced the release of its newest product offering reviewing the pipeline of active anti-B7-H4 immunotherapeutics in R&D: Pipeline of B7-H4-Targeted Immunotherapies. This competitive intelligence report about B7-H4-Targeted Immunotherapies...

Pipeline of Mesothelin-Targeted Immunotherapies

Mesothelin: an old solid tumor target for next generation drug modalities – a pipeline review STUTTGART, Germany I August 18, 2025 I La Merie Publishing announced the release of its newest product offering reviewing the pipeline of active anti-mesothelin immunotherapeutics in R&D: Pipeline of Mesothelin-Targeted Immunotherapies. This competitive intelligence report...

Pipeline of c-Met-Targeted Immunotherapies

c-Met: a well-suited target for payload delivery by antibodies – a pipeline review STUTTGART, Germany I August 15, 2025 I La Merie Publishing announced the release of its newest product offering reviewing the pipeline of active anti-c-Met immunotherapeutics in R&D: Pipeline of c-Met-Targeted Immunotherapies. This competitive intelligence report about c-Met-Targeted...

Pipeline of Her3-Targeted Immunotherapies

STUTTGART, Germany I August 14, 2025 I La Merie Publishing announced the release of its newest product offering reviewing the pipeline of active anti-Her3 immunotherapeutics in R&D: Pipeline of Her3-Targeted Immunotherapies. This competitive intelligence report about Her3-Targeted Immunotherapies provides a competitor evaluation in the field of product candidates in research...

Pipeline of DLL3-Targeted Immunotherapy

DLL3: competitors of clinically validated target develop effector-enhanced next generation product candidates STUTTGART, Germany I August 05, 2025 I La Merie Publishing released its newest product entitled: DLL3-Targeted Immunotherapy: a Competitor Analysis. DLL3 is a clinically validated target for treatment of small cell lung cancer which recently started commercialization. Delta-like...